Literature DB >> 1415311

Skin necrosis and protein C deficiency associated with vitamin K depletion in a patient with renal failure.

R Soundararajan1, D J Leehey, A W Yu, T S Ing, J B Miller.   

Abstract

Skin necrosis similar to that induced by warfarin was seen in a patient who had never received the drug but who was vitamin K-deficient due to malnutrition and prolonged treatment with broad-spectrum antibiotics. He also had end-stage renal failure and was receiving prophylactic subcutaneous heparin therapy because of immobilization. His plasma protein C antigen level and, disproportionately, his plasma protein C functional activity were decreased. Both protein C values improved after vitamin K therapy, discontinuation of heparin, and initiation of hemodialysis. We surmise that skin necrosis occurred as a result of protein C deficiency caused by vitamin K depletion. Production of abnormal (descarboxy) protein C/protein S due to vitamin K deficiency and increased protein C inhibitory activity associated with renal failure and/or heparin administration may have contributed to the clinical picture. This rare but serious complication of a relatively common disorder, viz., vitamin K deficiency, reinforces the importance of vitamin K supplementation in malnourished patients who receive long-term antibiotic maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415311     DOI: 10.1016/0002-9343(92)90179-f

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

Review 1.  Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.

Authors:  R Wütschert; P Piletta; H Bounameaux
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

2.  Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty.

Authors:  Salima Juma; Benjamin K A Thomson; Charmaine E Lok; Catherine M Clase; Peter G Blake; Louise Moist
Journal:  BMC Nephrol       Date:  2013-08-13       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.